Acorda Therapeutics says it will buy fellow drug maker Civitas Therapeutics for $525 million in cash, which will give Acorda rights to Civitas’ treatment candidate for episodes of Parkinson’s disease.
read more
Acorda Therapeutics says it will buy fellow drug maker Civitas Therapeutics for $525 million in cash, which will give Acorda rights to Civitas’ treatment candidate for episodes of Parkinson’s disease.
read more